STP705
Sponsors
Sirnaomics
Conditions
Abdominal ObesityBasal Cell CarcinomaBowen's DiseaseCholangiocarcinomaCutaneous Squamous Cell Carcinoma in SituFacial isSCCHepatocellular CarcinomaHypertrophic Scar
Phase 1
A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar
CompletedNCT02956317
Start: 2017-01-31End: 2018-01-31Updated: 2021-11-24
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC
CompletedNCT04293679
Start: 2019-03-21End: 2020-10-21Updated: 2022-06-09
Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
CompletedNCT04676633
Start: 2021-03-01End: 2023-01-13Updated: 2024-03-19
Safety, Tolerability, Pharmacokinetics, Immunogenicity and Efficacy of STP705 in Adult Patients With Hypertrophic Scars
NCT05196373
Start: 2023-06-30End: 2024-12-31Target: 50Updated: 2023-03-01
A Study to Evaluate Safety, Tolerability of Subcutaneous Injection in Adult Subjects Undergoing Abdominoplasty
CompletedNCT05422378
Start: 2022-08-01End: 2023-06-27Updated: 2024-03-18
Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC
CompletedNCT05421013
Start: 2022-08-01End: 2023-03-29Updated: 2024-03-18
Phase 2
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
CompletedNCT04669808
Start: 2020-12-28End: 2023-02-09Updated: 2024-03-18
A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC
CompletedNCT04844983
Start: 2021-05-18End: 2022-12-06Updated: 2024-03-18
A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence
CompletedNCT04844840
Start: 2021-04-29End: 2023-05-17Updated: 2024-03-19